Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5813417 | Neuropharmacology | 2016 | 42 Pages |
Abstract
The agonist properties of all the compounds were abolished or drastically reduced by the CB1 antagonist/inverse agonist AM251 (0.1 μM). No activation of G-protein was observed in CB1-KO mice. BB-22 (0.003-0.01 mg/kg i.v.) increased dialysate DA in the accumbens shell but not in the core or in the medial prefrontal cortex, with a bell shaped dose-response curve and an effect at 0.01 mg/kg and a biphasic time-course. Systemic AM251 (1.0 mg/kg i.p.) completely prevented the stimulant effect of BB-22 on dialysate DA in the NAc shell. All the other compounds increased dialysate DA in the NAc shell at doses consistent with their in vitro affinity for CB1 receptors (5F-PB-22, 0.01 mg/kg; 5F-AKB-48, 0.1 mg/kg; STS-135, 0.15 mg/kg i.v.). 3rd generation cannabinoids can be even more potent and super-high CB1 receptor agonists compared to JWH-018. Future research will try to establish if these properties can explain the high toxicity and lethality associated with these compounds.
Keywords
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Maria Antonietta De Luca, M. Paola Castelli, Barbara Loi, Alessandra Porcu, Mariella Martorelli, Cristina Miliano, Kathryn Kellett, Colin Davidson, Jacqueline L. Stair, Fabrizio Schifano, Gaetano Di Chiara,